Abstract：Objective To analyze specifications related to quality in ICH E2B (R3) guidelines and to find out about the data quality requirements of individual case safety reports. Methods Data elements in the ICH E2B (R3) guidelines were associated with human cognition. The whole process from data, information, knowledge and finally to wisdom was analyzed and demonstrated before factors and visual dimensions that affected data quality were determined. Results Data quality was embodied in data integrity (data dimension) and data accuracy (granularity). The requirements on data relationships and data elements in E2B (R3) guidelines could effectively guarantee the quality of individual case safety reports. Relevant design based on E2B (R3) guidelines could deliver high-quality data on drug safety. Conclusion When designing the safety information collection form, the marketing license applicant and MAH need to ensure data quality from the perspective of accuracy and integrity according to the ICH E2B (R3) implementation guidelines. High-quality data can be accumulated in the safety database to discover potential drug safety signals.
万帮喜, 余丽娜, 徐菊萍. 基于ICH E2B（R3）指南理解个例安全性报告数据质量[J]. 中国药物警戒, 2019, 16(10): 597-601.
WAN Bangxi, YU Lina, XU Juping. Data Quality of Individual Case Safety Reports Based on ICH E2B (R3) Implementation Guidelines. Chinese Journal of Pharmacovigilance, 2019, 16(10): 597-601.
[1] ICH.Maintenance of the ICH guideline on clinical safety data management: data elements for transmission of individual case safety reports E2B (R2)[EB/OL].(2001-01-05)[2019- 09-07]. https://wenku.baidu.com/view/4cebcd0fba1aa 8114431d947.html. [2] 武楠,杨悦.欧盟药物警戒数据库建设对我国的启示[J]. 中国药物警戒, 2018, 15(4): 230-233. [3] Hennig Renald.Electronic Reporting for Clinical Drug Safety and Pharmacovigilance[J].Expert Opinion on Drug Safety, 2003,2(2):195-197. [4] 叶小飞,郭晓晶,赵璐,等.个例安全性报告规范(ICH E2B)简介及应用[J].中国药物警戒,2012,9(3):149-151. [5] ICH.ICH M2工作组介绍[EB/OL].(2019-08)[2019-09-07]. http://estri.ich.org/index.html. [6] 荆宁宁,程俊瑜.数据、信息、知识与智慧[J].情报科学, 2005,23(12):1786-1790. [7] Ralph Edwards,Marie Lindquist Editors.Pharmacovigilance Critique and Ways Forward[M].Springer International Publishing Switzerland,2017:XV-XVi. [8] Lindquist D M.Data Quality Management in Pharmacovigilance[J]. Drug Safety,2004,27(12):857. [9] Nelson J C,Cook A J,Yu O,et al.Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data[J].Pharmacoepidemiology & Drug Safety, 2012, 21(S1):62-71. [10] Kelly W K,Halabi S.Reporing of Adverse Event[M].America: Springer Publishing Company,2018,141-149. [11] DIA.从生产企业角度如何改善临床试验中的安全性报 告[EB/OL]. (2018-06-07)[2019-09-07].https://mp.weixin.qq.com/s/86XN2FCB28S2OwUlyQi5Pg. [12] EU.EudraVigilance-European database of suspected adverse drug reaction report-Background[EB/OL].[2019-09-07]. http://www.adrreports.eu/en/background.html. [13] 蔡婷,闫磊,刘述森,等.我国药品上市后重点监测相关 问题的探讨[J].药物流行病学杂志, 2017，26(5): 5-9,32. [14] ICH.Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs) E2B(R3) Data Elements and Message Specification[EB/OL].(2016-11-10) [2019-09-07]. https://www.ich.org/products/guidelines/ efficacy/article/efficacy-guidelines.html. [15] NMPA.总局关于适用国际人用药品注册技术协调会二级 指导原则的公告(2018年第10号)[EB/OL].(2018-01-25) [2019-09-07]. http://www.nmpa.gov.cn/WS04/CL2138/ 300493.html.
2019, Vol. 16 
